Item 8.01 Other Events.

On May 18, 2023, Satsuma Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's 505(b)(2) New Drug Application ("NDA") for STS101 has been accepted for review by the U.S. Food and Drug Administration ("FDA"). A copy of the press release announcing the submission is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

Exhibit
  No.        Description

99.1           Press Release dated May 18, 2023

104          Cover Page Interactive Data File (embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses